Phase 1 Steatohepatitis Clinical Trials
15 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–15 of 15 trials
Recruiting
Phase 1
Evaluating the Pharmacokinetics and Safety of Miricorilant
Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis+1 more
Corcept Therapeutics15 enrolled1 locationNCT07553663
Recruiting
Phase 1Phase 2
Study of TGM-312-SC01 in Healthy Participants and Adults With MASH
Healthy ParticipantsMASH - Metabolic Dysfunction-Associated Steatohepatitis
Tangram Therapeutics Plc99 enrolled1 locationNCT07427680
Recruiting
Phase 1
A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects
Non Alcoholic Steatohepatitis
Sunshine Lake Pharma Co., Ltd.96 enrolled1 locationNCT07099118
Recruiting
Phase 1Phase 2
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis
Regeneron Pharmaceuticals132 enrolled3 locationsNCT06836609
Recruiting
Phase 1
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Nonalcoholic Steatohepatitis (NASH)Metabolic dysfunction-associated steatohepatitis (MASH)Non-alcoholic Fatty Liver Disease NAFLD+1 more
Corcept Therapeutics8 enrolled1 locationNCT06947304
Recruiting
Phase 1
ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants
Metabolic Dysfunction-Associated Steatohepatitis
Eccogene72 enrolled1 locationNCT07334080
Recruiting
Phase 1
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）
NASH - Nonalcoholic SteatohepatitisNAFLD - Non-Alcoholic Fatty Liver Disease
Tasly Biopharmaceuticals Co., Ltd.32 enrolled5 locationsNCT07128797
Recruiting
Phase 1
To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects
Nonalcoholic Steatohepatitis (NASH)
Changchun Intellicrown Pharmaceutical Co. LTD138 enrolled1 locationNCT06216041
Recruiting
Phase 1
A Study of INI-822 in Healthy Volunteers and Participants with Non-alcoholic Steatohepatitis (NASH) or Presumed NASH
Non Alcoholic Steatohepatitis
Inipharm Australia Pty Ltd104 enrolled7 locationsNCT05945537
Recruiting
Phase 1
Safety of DNP007 in Healthy Subjects
Liver Transplant; ComplicationsSteatohepatitis, NonalcoholicLiver Transplant Rejection
Seoul National University Hospital12 enrolled1 locationNCT06400771
Recruiting
Phase 1Phase 2
Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis
Steatohepatitis, NonalcoholicFatty Liver Disease
Sadat City University46 enrolled1 locationNCT06302049
Completed
Phase 1
A first in human study to Evaluate the Safety and Tolerability of OLX75016 for treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis.
(NAFLD) to steatohepatitis (NASH)Cirrhosis
OliX AU Pty Ltd58 enrolled1 locationACTRN12624000023550
Not Yet Recruiting
Phase 1
A Randomized, Double-blind, Placebo- controlled, Single Ascending Dose (SAD) Study of XW003 Injection in Healthy Adult Participants
Type 2 Diabetes MellitusNonalcoholic Steatohepatitis
Sciwind Biosciences APAC CO Pty. Ltd.50 enrolled1 locationACTRN12620000344998
Completed
Phase 1
A Phase 1 Open-Label, Parallel-Group, Two-Treatment, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9674 and GS-0976 in Subjects with Normal Renal Function and Severe Renal Impairment
Nonalcoholic Steatohepatitis (NASH)
Gilead Sciences Inc20 enrolled4 locationsACTRN12619000655145
Completed
Phase 1
A Single Oral Dose Study of DUR-928 in Nonalcoholic Steatohepatitis (NASH) Patients and Healthy Volunteers
Nonalcoholic Steatohepatitis (NASH)
INC Research32 enrolled1 locationACTRN12615001355561